TRDA
Entrada Therapeutics Inc
5.50$
-1.4%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | – | – | – | – | -28.1% | +140.7% | -4.3% | +41.3% | +60.2% | -79.3% | +91.1% | -45.0% | -90.5% | -17.2% | -19.5% | -32.6% | +2.6% | – | |
| – | – | – | – | – | – | – | – | – | – | +0.0% | +5.0% | +4,300.4% | +13.8% | -15.6% | -96.7% | +26.9% | -3.6% | +0.0% | +10.2% | – | – | +3,387.4% | -97.7% | -9.1% | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | -476.7% | – | +94.2% | +41.3% | +60.2% | -79.3% | +91.1% | -45.0% | -90.5% | -1,984.5% | – | -83.1% | +1,182.9% | – | |
| – | +0.0% | +30.3% | +16.8% | -6.5% | +9.7% | +53.9% | +17.6% | +27.1% | +3.4% | +16.7% | -17.3% | +47.3% | +13.8% | -15.6% | +27.5% | +1.1% | +12.0% | -2.4% | +6.9% | -4.0% | +18.1% | +1.3% | -11.5% | -2.7% | +7.0% | – | |
| – | +0.0% | +10.9% | +56.9% | +8.7% | +42.0% | +25.0% | +58.3% | +5.5% | +14.0% | -4.9% | +41.8% | -19.8% | +2.9% | -7.8% | +14.9% | +8.6% | -1.7% | +8.0% | -1.1% | +4.2% | +6.3% | -5.7% | -7.3% | +6.0% | +3.6% | – | |
| – | +0.0% | +26.3% | +24.1% | -3.0% | +18.1% | +44.9% | +28.5% | +20.0% | +6.5% | +10.0% | -1.4% | -69.0% | +2.9% | -7.8% | +390.5% | +2.9% | +8.6% | -0.1% | +4.9% | -2.1% | +15.2% | -78.9% | +313.6% | -0.6% | +8.2% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -65.0% | +330.4% | +153.0% | -140.5% | – | – | – | – | – | – | – | – | |
| – | – | – | +17.6% | -35.0% | -30.8% | +633.3% | -80.3% | +3,592.3% | -16.0% | +98.3% | +18.9% | +367.9% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -82.6% | +175.4% | +128.2% | -127.5% | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | +289.9% | +25.6% | +7.7% | -90.2% | +50.6% | -167.4% | – | – | – | +267.4% | -85.9% | -58.7% | -7.9% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -126.9% | – | +134.2% | -125.5% | – | -1,634.0% | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -81.5% | +164.4% | +123.5% | -125.5% | – | -6,583.4% | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.